Table 1.
Characteristics of DMF-treated and lymphopenic (grade 3) patient cohort (n = 11). Multiple linear regression analysis (MVreg) for the outcome variable ‘duration until reaching lymphocyte recovery in days’ was run. Lymphocyte recovery was defined as lymphocyte count ⩾800/µl. MVreg was adjusted for sex and duration of DMF treatment (days). R2 (MVreg): 0.69, n = 11.
| Mean (95% CI) | Range | |
|---|---|---|
| Age (years) | 49.8 (40.4–59.3) | 22.7–71.8 |
| Duration of DMF treatment (days) | 501.9 (288.4–715.4) | 172–1064 |
| Dosage of DMF (mg) | 480 (480–480) | 480–480 |
| Time until lymphocyte counts ⩾800 µl (days) | 71.2 (24.5–117.8) | 9–180 |
| N | % | |
| Diagnosis (RRMS) | 11/11 | 100 |
| Sex (female) | 8/11 | 72.7 |
| Immunotherapy prior to DMF | ||
| None | 6/11 | 54.5 |
| Interferon | 4/11 | 36.4 |
| Natalizumab | 1/11 | 9.1 |
| Coefficient (95% CI) | p value | |
| Multiple Linear Regression Analysis | ||
| Age at DMF withdrawal (years) | 4.07 (1.26–6.87) | 0.01 |
CI, confidence interval; DMF, dimethyl fumarate; MVreg, multiple linear regression analysis; N, number of observations; RRMS, relapsing–remitting multiple sclerosis.